Spots Global Cancer Trial Database for ruxolitinib
Every month we try and update this database with for ruxolitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | NCT05413356 | Bronchiolitis O... Hematologic Mal... | Ruxolitinib | 18 Years - 65 Years | First Affiliated Hospital of Zhejiang University | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Study of Ruxolitinib in Colorectal Cancer Patients | NCT02119676 | CRC (Colorectal... | Ruxolitinib Regorafenib Placebo | 18 Years - | Incyte Corporation | |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | NCT02974647 | Lymphoma | Ruxolitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | NCT02120417 | Breast Cancer | Ruxolitinib Capecitabine Placebo | 18 Years - | Incyte Corporation | |
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04454658 | Myelofibrosis (... | ABBV-744 Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | NCT00952289 | MPN (Myeloproli... | Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | NCT02912754 | Leukemia, Lymph... | ruxolitinib ibrutinib | 19 Years - | Sunnybrook Health Sciences Centre | |
| Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | NCT05592015 | T-Cell Large Gr... | Ruxolitinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | NCT04217356 | Myelofibrosis High-Risk Cance... Bone Marrow Can... | Hematopoietic s... Ruxolitinib Hydroxyurea | 18 Years - 70 Years | University Health Network, Toronto | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | NCT01751425 | Chronic Myeloge... Chronic Myeloge... Minimal Residua... Philadelphia Ch... | Dasatinib Imatinib Mesyla... Nilotinib Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | NCT05269771 | Polycythemia Ve... | Ruxolitinib | 12 Years - 99 Years | Novartis | |
| A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | NCT02973711 | Leukemia, Chron... | Nilotinib Ruxolitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | NCT02718300 | MPN (Myeloproli... | Parsaclisib Parsaclisib Ruxolitinib Parsaclisib Parsaclisib | 18 Years - | Incyte Corporation | |
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | NCT01981850 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | RO7490677 Ruxolitinib | 18 Years - | Hoffmann-La Roche | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | NCT01969838 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Momelotinib Ruxolitinib Placebo to matc... Placebo to matc... | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | NCT00638378 | Prostate Cancer | Ruxolitinib | 18 Years - | Incyte Corporation | |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | NCT02292446 | Polycythemia Ve... | Ruxolitinib | 18 Years - | Novartis | |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | NCT01340651 | Myelofibrosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | NCT02253277 | Chronic Myeloid... | Nilotinib Ruxolitinib | 18 Years - | Novartis | |
| Phase l/II Study of Ruxolitinib for Acute Leukemia | NCT01251965 | Leukemia | Ruxolitinib | 14 Years - | M.D. Anderson Cancer Center | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| Study of Ruxolitinib in Pancreatic Cancer Patients | NCT01423604 | Pancreatic Canc... | Capecitabine Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | NCT02912754 | Leukemia, Lymph... | ruxolitinib ibrutinib | 19 Years - | Sunnybrook Health Sciences Centre | |
| A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | NCT01877005 | Hodgkin's Lymph... | Ruxolitinib | 18 Years - | The Lymphoma Academic Research Organisation | |
| Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT03674047 | Other Cancer | ruxolitinib | 18 Years - 75 Years | Massachusetts General Hospital | |
| Study of Ruxolitinib in Pancreatic Cancer Patients | NCT01423604 | Pancreatic Canc... | Capecitabine Ruxolitinib Placebo | 18 Years - | Incyte Corporation | |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | NCT05936359 | Myeloproliferat... | INCA033989 Ruxolitinib | 18 Years - | Incyte Corporation | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia | NCT02577926 | Polycythemia Ve... Essential Throm... | Ruxolitinib BAT | 18 Years - | RWTH Aachen University | |
| An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | NCT01822756 | Solid Tumors Pancreatic Canc... | ruxolitinib gemcitabine nab-paclitaxel filgrastim | 18 Years - | Incyte Corporation | |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | NCT05010005 | T-cell Lymphoma... NK-Cell Lymphom... T-cell Prolymph... T-cell Large Gr... | Ruxolitinib Duvelisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | NCT05421104 | Polycythemia Ve... | Ruxolitinib | 18 Years - 99 Years | Novartis | |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | NCT04485260 | Myelofibrosis | KRT-232 Ruxolitinib | 18 Years - 99 Years | Kartos Therapeutics, Inc. | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | NCT04744116 | Hematopoietic a... Steroid Refract... | Cellular Therap... Ruxolitinib | 12 Years - 80 Years | M.D. Anderson Cancer Center | |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | NCT02955940 | Pancreatic Canc... Colorectal Canc... Breast Cancer Lung Cancer | Ruxolitinib Capecitabine Regorafenib | 18 Years - | Incyte Corporation | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | NCT02593929 | Head and Neck S... | ruxolitinib | 18 Years - | University of Pittsburgh | |
| A Study of Ruxolitinib in Pancreatic Cancer Patients | NCT02119663 | Pancreatic Canc... | Ruxolitinib Placebo Capecitabine | 18 Years - | Incyte Corporation | |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | NCT04472598 | Myelofibrosis (... | Navitoclax Ruxolitinib Placebo for Nav... | 18 Years - | AbbVie | |
| Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | NCT02117479 | Pancreatic Canc... | Ruxolitinib Placebo Capecitabine | 18 Years - | Incyte Corporation | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera | NCT04644211 | Essential Throm... Polycythemia Ve... | Ruxolitinib | 18 Years - | Massachusetts General Hospital | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | NCT03286530 | Acute Myeloid L... Acute Myeloid L... Allogeneic Stem... | Ruxolitinib | 60 Years - 80 Years | Massachusetts General Hospital | |
| Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03874052 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Ruxolitinib Venetoclax | 18 Years - | OHSU Knight Cancer Institute | |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | NCT02613598 | Hodgkin's Lymph... Lymphoma, Non-H... | Bortezomib Ruxolitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | NCT04807777 | Advanced Cutane... | Ruxolitinib | 18 Years - | Columbia University | |
| A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | NCT03194542 | Primary Myelofi... Anemia | Luspatercept | 18 Years - | Celgene | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | NCT03878199 | Essential Throm... Myelofibrosis Myeloproliferat... Polycythemia Ve... Secondary Acute... | Allogeneic Hema... Liposome-encaps... Ruxolitinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | NCT00509899 | Myelofibrosis Polycythemia Ve... Thrombocytosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | NCT02038036 | Polycythemia Ve... | Best Available ... Ruxolitinib | 18 Years - | Novartis | |
| Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | NCT04744116 | Hematopoietic a... Steroid Refract... | Cellular Therap... Ruxolitinib | 12 Years - 80 Years | M.D. Anderson Cancer Center | |
| Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT03681561 | Hodgkin Lymphom... | Ruxolitinib Nivolumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01895842 | Leukemia | Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | NCT03610971 | Chronic Phase C... Chronic Myeloid... | Ruxolitinib BCR-ABL Tyrosin... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | NCT02120417 | Breast Cancer | Ruxolitinib Capecitabine Placebo | 18 Years - | Incyte Corporation | |
| PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT | NCT04669210 | Graft-versus-ho... Stem Cell Trans... Acute Myeloid L... Acute Lymphoid ... | Ruxolitinib Tacrolimus Mycophenolate M... | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | NCT06225310 | Multiple Myelom... Multiple Myelom... | Selinexor Ruxolitinib Methylprednisol... | - | Oncotherapeutics | |
| Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | NCT03613428 | Acute T Cell Le... | Ruxolitinib Vincristine Prednisone | 13 Years - 75 Years | Sichuan University | |
| A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera | NCT05853445 | Polycythemia Ve... | Jakavi | 18 Years - 120 Years | Novartis | |
| Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases. | NCT02072057 | Cancer Cachexia | Ruxolitinib | 18 Years - | Kantonsspital Aarau | |
| JAK-inhibition in Recurrent Classical Hodgkin Lymphoma | NCT02164500 | Recurrent Class... | Ruxolitinib | 18 Years - 99 Years | University of Cologne | |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | NCT03286530 | Acute Myeloid L... Acute Myeloid L... Allogeneic Stem... | Ruxolitinib | 60 Years - 80 Years | Massachusetts General Hospital | |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | NCT01914484 | Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Po... Resistant to Ty... | Nilotinib Ruxolitinib | 18 Years - | University Health Network, Toronto | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| Ruxolitinib in Patients With Breast Cancer | NCT01562873 | Breast Cancer | Ruxolitinib | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
